| Autor: |
Feemster K; Merck & Co., Inc., Rahway, NJ 07065, USA., Weaver J; Merck & Co., Inc., Rahway, NJ 07065, USA., Buchwald U; Merck & Co., Inc., Rahway, NJ 07065, USA., Banniettis N; Merck & Co., Inc., Rahway, NJ 07065, USA., Cox KS; Merck & Co., Inc., Rahway, NJ 07065, USA., McIntosh ED; MSD (UK) Limited, London EC2M 6UR, UK., Spoulou V; Immunobiology and Vaccinology Research Laboratory, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. |
| Abstrakt: |
Globally, Streptococcus pneumoniae is a leading cause of vaccine-preventable morbidity and mortality in infants and children. In recent decades, large-scale pediatric immunization programs have substantially reduced the incidence of invasive pneumococcal disease. Despite this, residual vaccine-type pneumococcal disease remains in the form of vaccine breakthrough and vaccine failure. This targeted literature review aims to discuss aspects of vaccine breakthrough and failure in infants and children, including disease epidemiology, clinical presentation, risk factors, vaccination schedules, vaccine serotypes, correlates of protection, comorbidities, disease surveillance, and potential implications for future vaccine development. |
